The July/August issue of Pharmafocus is now live!

pharmafile | July 4, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Elizabeth Holmes, NHS, Sanofi, Theranos, UK, ambien, manufacturing compliance, opdivo, patient recruitment, patient retention, pharma 

The new July/August edition of Pharmafocus is now available to read online.

As cross- and inter-party squabbles ramp up and negotiations become ever more weighted with ominous importance, the day the UK will officially exit the European Union grows ever closer. And while we are still no closer to knowing what that exit will actually mean, the UK Government has announced an abrupt about-turn to backpedal on almost a decade of starving the NHS and inject £20 billion of funding into the health service. But the assertion that this sum will be derived from a Brexit dividend have been met with considerable scepticism, with it much more likely to come from a tax hike instead. Can the promise be delivered? You can check out the full story on our front page.

On the other side of the world, there was a breakthrough for Chinese citizens living with cancer as Bristol-Myers Squibb revealed that its blockbuster immunotherapy Opdivo had secured approval in the nation. The momentous decision marked the first approval of such a therapy, as well as the first PD-1 inhibitor. It could mean great things – you can read more on page 7.

You can find many more of the industry’s top news inside, from the indictment of Theranos founder Elizabeth Holmes on fraud charges to Sanofi’s tongue-in-cheek defense of its product Ambien following the implosion of hit US show Roseanne after its namesake and star made racist outbursts over Twitter. And don’t miss our full-length features on manufacturing compliance, patient recruitment and retention, and the importance of pushing for diversity in the biotech sector.

Read the July/August edition of Pharmafocus online now!

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Latest content